Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries (BioDrugs, (2024), 38, 1, (133-144), 10.1007/s40259-023-00636-z)

Hyunjung Woo; Gyeongseon Shin; Donghwan Lee; Hye Young Kwon; Seung Jin Bae

doi:10.1007/s40259-024-00645-6

Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries (BioDrugs, (2024), 38, 1, (133-144), 10.1007/s40259-023-00636-z)

Hyunjung Woo
, Gyeongseon Shin
, Donghwan Lee
, Hye Young Kwon
, Seung Jin Bae

Research output: Contribution to journal › Comment/debate

Abstract

Declarations section: The Funding statement that previously read Funding This work was supported by the National Research Foundation (NRF-2021R1F1A10502). should read Funding This work was supported by the National Research Foundation (NRF-2021R1F1A1050281). The original article has corrected.

Original language	English
Pages (from-to)	323
Number of pages	1
Journal	BioDrugs
Volume	38
Issue number	2
DOIs	https://doi.org/10.1007/s40259-024-00645-6
State	Published - Mar 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2024.

Access to Document

10.1007/s40259-024-00645-6

Fingerprint

Dive into the research topics of 'Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries (BioDrugs, (2024), 38, 1, (133-144), 10.1007/s40259-023-00636-z)'. Together they form a unique fingerprint.

Cite this

@article{0cca1ca7615245fdbfc6974fd5583b2e,

title = "Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries (BioDrugs, (2024), 38, 1, (133-144), 10.1007/s40259-023-00636-z)",

abstract = "Declarations section: The Funding statement that previously read Funding This work was supported by the National Research Foundation (NRF-2021R1F1A10502). should read Funding This work was supported by the National Research Foundation (NRF-2021R1F1A1050281). The original article has corrected.",

author = "Hyunjung Woo and Gyeongseon Shin and Donghwan Lee and Kwon, \{Hye Young\} and Bae, \{Seung Jin\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = mar,

doi = "10.1007/s40259-024-00645-6",

language = "English",

volume = "38",

pages = "323",

journal = "BioDrugs",

issn = "1173-8804",

publisher = "Adis",

number = "2",

}

Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries (BioDrugs, (2024), 38, 1, (133-144), 10.1007/s40259-023-00636-z). / Woo, Hyunjung; Shin, Gyeongseon; Lee, Donghwan et al.
In: BioDrugs, Vol. 38, No. 2, 03.2024, p. 323.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries (BioDrugs, (2024), 38, 1, (133-144), 10.1007/s40259-023-00636-z)

AU - Woo, Hyunjung

AU - Shin, Gyeongseon

AU - Lee, Donghwan

AU - Kwon, Hye Young

AU - Bae, Seung Jin

PY - 2024/3

Y1 - 2024/3

N2 - Declarations section: The Funding statement that previously read Funding This work was supported by the National Research Foundation (NRF-2021R1F1A10502). should read Funding This work was supported by the National Research Foundation (NRF-2021R1F1A1050281). The original article has corrected.

AB - Declarations section: The Funding statement that previously read Funding This work was supported by the National Research Foundation (NRF-2021R1F1A10502). should read Funding This work was supported by the National Research Foundation (NRF-2021R1F1A1050281). The original article has corrected.

UR - https://www.scopus.com/pages/publications/85182851632

U2 - 10.1007/s40259-024-00645-6

DO - 10.1007/s40259-024-00645-6

M3 - Comment/debate

C2 - 38252342

AN - SCOPUS:85182851632

SN - 1173-8804

VL - 38

SP - 323

JO - BioDrugs

JF - BioDrugs

IS - 2

ER -